{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:18:33Z","timestamp":1791580713351,"version":"4.3.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,27]]},"DOI":"10.7759\/cureus.81319","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T05:18:22Z","timestamp":1743139102000},"source":"Crossref","is-referenced-by-count":2,"title":["Optimizing Anticoagulation Strategies in Patients With Atrial Fibrillation and Valvular Heart Disease: A Comprehensive Evidence-Based Review"],"prefix":"10.7759","author":[{"given":"Dharani S","family":"Deiveegan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Salahie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Subhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulman","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abdullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshankumar M","family":"Raval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyla","family":"Betsy Baiju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam K","family":"Abuasaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruqiya","family":"Bibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvw037","article-title":"Anticoagulation, atherosclerosis, and heart failure","volume":"3","author":"Agewall S","year":"2017","unstructured":"Agewall S. Anticoagulation, atherosclerosis, and heart failure. Eur Heart J Cardiovasc Pharmacother. 2017, 3:1-2. 10.1093\/ehjcvp\/pvw037","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003336.pub4","article-title":"Anticoagulation versus placebo for heart failure in sinus rhythm","volume":"5","author":"Shantsila E","year":"2021","unstructured":"Shantsila E, Kozie\u0142 M, Lip GY. Anticoagulation versus placebo for heart failure in sinus rhythm. Cochrane Database Syst Rev. 2021, 5:003336. 10.1002\/14651858.CD003336.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-314381","article-title":"Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis","volume":"105","author":"Beggs SA","year":"2019","unstructured":"Beggs SA, R\u00f8rth R, Gardner RS, McMurray JJ. Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis. Heart. 2019, 105:1325-34. 10.1136\/heartjnl-2018-314381","journal-title":"Heart"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-018-9693-0","article-title":"Anticoagulation in atrial fibrillation with heart failure","volume":"23","author":"Zhao L","year":"2018","unstructured":"Zhao L, Wang WY, Yang X. Anticoagulation in atrial fibrillation with heart failure. Heart Fail Rev. 2018, 23:563-71. 10.1007\/s10741-018-9693-0","journal-title":"Heart Fail Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.13244.2","article-title":"A retrospective study on atrial fibrillation after coronary artery bypass grafting surgery at The National Heart Institute, Kuala Lumpur","volume":"7","author":"Farouk Musa A","year":"2018","unstructured":"Farouk Musa A, Quan CZ, Xin LZ, Soni T, Dillon J, Hay YK, Nordin RB. A retrospective study on atrial fibrillation after coronary artery bypass grafting surgery at The National Heart Institute, Kuala Lumpur. F1000Res. 2018, 7:164. 10.12688\/f1000research.13244.2","journal-title":"F1000Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14060571","article-title":"Atrial fibrillation and mortality after gastrointestinal surgery: insights from a systematic review and meta-analysis","volume":"14","author":"Palc\u0103u AC","year":"2024","unstructured":"Palc\u0103u AC, \u0218erb\u0103noiu LI, Ion D, et al.. Atrial fibrillation and mortality after gastrointestinal surgery: insights from a systematic review and meta-analysis. J Pers Med. 2024, 14:571-10. 10.3390\/jpm14060571","journal-title":"J Pers Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45881","article-title":"The synergistic relationship between atrial fibrillation and diabetes mellitus: implications for cardiovascular and metabolic health","volume":"15","author":"Mohsin M","year":"2023","unstructured":"Mohsin M, Zeyad H, Khalid H, et al.. The synergistic relationship between atrial fibrillation and diabetes mellitus: implications for cardiovascular and metabolic health. Cureus. 2023, 15:45881. 10.7759\/cureus.45881","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/164_2016_126","article-title":"Anticoagulation therapy and NOACs in heart failure","volume":"243","author":"Thomas I","year":"2017","unstructured":"Thomas I, EncisoSilva J, Schlueter M, Greenberg B. Anticoagulation therapy and NOACs in heart failure. Handb Exp Pharmacol. 2017, 243:515-35. 10.1007\/164_2016_126","journal-title":"Handb Exp Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1153","article-title":"Anticoagulation in heart failure without atrial fibrillation: gaps and dilemmas in current clinical practice","volume":"20","author":"Siliste RN","year":"2018","unstructured":"Siliste RN, Antohi EL, Pepoyan S, Nakou E, Vardas P. Anticoagulation in heart failure without atrial fibrillation: gaps and dilemmas in current clinical practice. Eur J Heart Fail. 2018, 20:978-88. 10.1002\/ejhf.1153","journal-title":"Eur J Heart Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14550","article-title":"Clinical outcomes and anticoagulation therapy in elderly non-valvular atrial fibrillation and heart failure patients","volume":"11","author":"Ikeda S","year":"2024","unstructured":"Ikeda S, Hiasa KI, Inoue H, et al.. Clinical outcomes and anticoagulation therapy in elderly non-valvular atrial fibrillation and heart failure patients. ESC Heart Fail. 2024, 11:902-13. 10.1002\/ehf2.14550","journal-title":"ESC Heart Fail"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-021-01930-y","article-title":"Anticoagulants for stroke prevention in heart failure with reduced ejection fraction","volume":"111","author":"Sch\u00e4fer A","year":"2022","unstructured":"Sch\u00e4fer A, Flierl U, Bauersachs J. Anticoagulants for stroke prevention in heart failure with reduced ejection fraction. Clin Res Cardiol. 2022, 111:1-13. 10.1007\/s00392-021-01930-y","journal-title":"Clin Res Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.033910","article-title":"Association of oral anticoagulation with stroke in atrial fibrillation or heart failure: a comparative meta-analysis","volume":"52","author":"Reddin C","year":"2021","unstructured":"Reddin C, Judge C, Loughlin E, et al.. Association of oral anticoagulation with stroke in atrial fibrillation or heart failure: a comparative meta-analysis. Stroke. 2021, 52:3151-62. 10.1161\/STROKEAHA.120.033910","journal-title":"Stroke"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz523","article-title":"Stroke prevention by low-dose anticoagulation in patients with heart failure and sinus rhythm: is it worth the effort?","volume":"40","author":"Maggioni AP","year":"2019","unstructured":"Maggioni AP, Andreotti F. Stroke prevention by low-dose anticoagulation in patients with heart failure and sinus rhythm: is it worth the effort?. Eur Heart J. 2019, 40:3602-4. 10.1093\/eurheartj\/ehz523","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/1747493019877296","article-title":"Oral anticoagulation versus antiplatelet or placebo for stroke prevention in patients with heart failure and sinus rhythm: Systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Ntaios G","year":"2019","unstructured":"Ntaios G, Vemmos K, Lip GY. Oral anticoagulation versus antiplatelet or placebo for stroke prevention in patients with heart failure and sinus rhythm: Systematic review and meta-analysis of randomized controlled trials. Int J Stroke. 2019, 14:856-61. 10.1177\/1747493019877296","journal-title":"Int J Stroke"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2018-000800","article-title":"Efficacy and safety of dabigatran versus warfarin from the RE-LY trial","volume":"5","author":"Avezum A","year":"2018","unstructured":"Avezum A, Oliveira GB, Diaz R, et al.. Efficacy and safety of dabigatran versus warfarin from the RE-LY trial. Open Heart. 2018, 5:000800. 10.1136\/openhrt-2018-000800","journal-title":"Open Heart"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131591","article-title":"Anticoagulation in patients with atrial fibrillation and heart failure: more than meets the eye?","volume":"397","author":"Alexandrino FB","year":"2024","unstructured":"Alexandrino FB, Faaborg-Andersen CC, daSilva-deAbreu A. Anticoagulation in patients with atrial fibrillation and heart failure: more than meets the eye?. Int J Cardiol. 2024, 397:131591. 10.1016\/j.ijcard.2023.131591","journal-title":"Int J Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3810\/hp.2011.10.918","article-title":"Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence","volume":"39","author":"Yates SW","year":"2011","unstructured":"Yates SW. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence. Hosp Pract (1995). 2011, 39:7-16. 10.3810\/hp.2011.10.918","journal-title":"Hosp Pract (1995)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008987","article-title":"Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - Timi 48 trial","volume":"7","author":"Fanola CL","year":"2018","unstructured":"Fanola CL, Ruff CT, Murphy SA, et al.. Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - Timi 48 trial. J Am Heart Assoc. 2018, 7:008987. 10.1161\/JAHA.118.008987","journal-title":"J Am Heart Assoc"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0452-4","article-title":"Direct oral anticoagulants for the prevention of stroke in patients with nonvalvular atrial fibrillation: understanding differences and similarities","volume":"75","author":"Dobesh PP","year":"2015","unstructured":"Dobesh PP, Fanikos J. Direct oral anticoagulants for the prevention of stroke in patients with nonvalvular atrial fibrillation: understanding differences and similarities. Drugs. 2015, 75:1627-44. 10.1007\/s40265-015-0452-4","journal-title":"Drugs"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001058","article-title":"Correction to: Direct oral anticoagulants versus Warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","year":"2022","unstructured":"Correction to. Direct oral anticoagulants versus Warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022, 145:640. 10.1161\/CIR.0000000000001058","journal-title":"Circulation"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123231","article-title":"Heart failure and stroke: the underrepresentation of the heart failure with preserved ejection fraction subtype in randomized clinical trials of therapeutic anticoagulation","volume":"466","author":"Kargiotis O","year":"2024","unstructured":"Kargiotis O, Safouris A, Psychogios K, et al.. Heart failure and stroke: the underrepresentation of the heart failure with preserved ejection fraction subtype in randomized clinical trials of therapeutic anticoagulation. J Neurol Sci. 2024, 466:123231. 10.1016\/j.jns.2024.123231","journal-title":"J Neurol Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae373","article-title":"Atrial fibrillation burden: a new outcome predictor and therapeutic target","volume":"45","author":"Becher N","year":"2024","unstructured":"Becher N, Metzner A, Toennis T, Kirchhof P, Schnabel RB. Atrial fibrillation burden: a new outcome predictor and therapeutic target. Eur Heart J. 2024, 45:2824-38. 10.1093\/eurheartj\/ehae373","journal-title":"Eur Heart J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2015.08.017","article-title":"Heart failure, nonvalvular atrial fibrillation and anticoagulation control with vitamin K antagonists","volume":"69","author":"Anguita S\u00e1nchez M","year":"2016","unstructured":"Anguita S\u00e1nchez M, Bertomeu Mart\u00ednez V, Cequier Fillat \u00c1. Heart failure, nonvalvular atrial fibrillation and anticoagulation control with vitamin K antagonists. Rev Esp Cardiol (Engl Ed). 2016, 69:75-6. 10.1016\/j.rec.2015.08.017","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2018.07.010","article-title":"International normalized ratio and mortality risk in acute heart failure and nonvalvular atrial fibrillation patients receiving vitamin K antagonists","volume":"72","author":"Santas E","year":"2019","unstructured":"Santas E, Mi\u00f1ana G, Gummel J, et al.. International normalized ratio and mortality risk in acute heart failure and nonvalvular atrial fibrillation patients receiving vitamin K antagonists. Rev Esp Cardiol (Engl Ed). 2019, 72:616-24. 10.1016\/j.rec.2018.07.010","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon W","year":"2019","unstructured":"Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet. 2019, 58:1265-79. 10.1007\/s40262-019-00775-z","journal-title":"Clin Pharmacokinet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.07.009","article-title":"Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"22","author":"Levy JH","year":"2024","unstructured":"Levy JH, Shaw JR, Castellucci LA, et al.. Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2024, 22:2889-99. 10.1016\/j.jtha.2024.07.009","journal-title":"J Thromb Haemost"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.066360","article-title":"Edoxaban for 12 months versus 3 months in patients with cancer with isolated distal deep vein thrombosis (onco DVT study): an open-label, multicenter, randomized clinical trial","volume":"148","author":"Yamashita Y","year":"2023","unstructured":"Yamashita Y, Morimoto T, Muraoka N, et al.. Edoxaban for 12 months versus 3 months in patients with cancer with isolated distal deep vein thrombosis (onco DVT study): an open-label, multicenter, randomized clinical trial. Circulation. 2023, 148:1665-76. 10.1161\/CIRCULATIONAHA.123.066360","journal-title":"Circulation"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.05.023","article-title":"Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH","volume":"22","author":"Carlin S","year":"2024","unstructured":"Carlin S, Cuker A, Gatt A, et al.. Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH. J Thromb Haemost. 2024, 22:2653-69. 10.1016\/j.jtha.2024.05.023","journal-title":"J Thromb Haemost"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003244","article-title":"Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)","volume":"4","author":"Connor P","year":"2020","unstructured":"Connor P, S\u00e1nchez van Kammen M, Lensing AW, et al.. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Adv. 2020, 4:6250-8. 10.1182\/bloodadvances.2020003244","journal-title":"Blood Adv"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209949","article-title":"Anticoagulation vs antiplatelets across subgroups of embolic stroke of undetermined source: a meta-analysis of randomized controlled trials","volume":"103","author":"Ghannam M","year":"2024","unstructured":"Ghannam M, Al-Qudah AM, Alshaer QN, et al.. Anticoagulation vs antiplatelets across subgroups of embolic stroke of undetermined source: a meta-analysis of randomized controlled trials. Neurology. 2024, 103:209949. 10.1212\/WNL.0000000000209949","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2099","article-title":"Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the patient-centered research into outcomes stroke patients prefer and effectiveness research (Prosper) study","volume":"76","author":"Xian Y","year":"2019","unstructured":"Xian Y, Xu H, O'Brien EC, et al.. Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the patient-centered research into outcomes stroke patients prefer and effectiveness research (Prosper) study. JAMA Neurol. 2019, 76:1192-202. 10.1001\/jamaneurol.2019.2099","journal-title":"JAMA Neurol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.1793","article-title":"Dose reduction of edoxaban in patients 80 years and older with atrial fibrillation: post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial","volume":"9","author":"Zimerman A","year":"2024","unstructured":"Zimerman A, Braunwald E, Steffel J, et al.. Dose reduction of edoxaban in patients 80 years and older with atrial fibrillation: post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial. JAMA Cardiol. 2024, 9:817-25. 10.1001\/jamacardio.2024.1793","journal-title":"JAMA Cardiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2023.08.076","article-title":"Aspirin versus warfarin after transcatheter aortic valve replacement in low-risk patients: 2-year follow-up","volume":"206","author":"Merdler I","year":"2023","unstructured":"Merdler I, Rogers T, Case BC, et al.. Aspirin versus warfarin after transcatheter aortic valve replacement in low-risk patients: 2-year follow-up. Am J Cardiol. 2023, 206:108-15. 10.1016\/j.amjcard.2023.08.076","journal-title":"Am J Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03206-0","article-title":"Role of anticoagulation therapy in modifying stroke risk associated with new-onset atrial fibrillation after non-cardiac surgery","volume":"30","author":"Azimaraghi O","year":"2024","unstructured":"Azimaraghi O, Rudolph MI, Wongtangman K, et al.. Role of anticoagulation therapy in modifying stroke risk associated with new-onset atrial fibrillation after non-cardiac surgery. Nat Med. 2024, 30:3310-7. 10.1038\/s41591-024-03206-0","journal-title":"Nat Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-3175-1_24","article-title":"Assays to monitor bivalirudin","volume":"2663","author":"Davidson S","year":"2023","unstructured":"Davidson S. Assays to monitor bivalirudin. Methods Mol Biol. 2023, 2663:369-80. 10.1007\/978-1-0716-3175-1_24","journal-title":"Methods Mol Biol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2505","article-title":"Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care","volume":"362","author":"Vinogradova Y","year":"2018","unstructured":"Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018, 362:2505. 10.1136\/bmj.k2505","journal-title":"BMJ"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"9","author":"Piccini JP","year":"2022","unstructured":"Piccini JP, Caso V, Connolly SJ, et al.. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 2022, 9:1383-90. 10.1016\/S0140-6736(22)00456-1","journal-title":"Lancet"},{"key":"ref38","unstructured":"PROGRESSIVE-AF, RAPID, NOVA, EHANCE-AF Trials Focus on Improving Treatment of Atrial and Supraventricular Arrhythmias. (2022). https.\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2022\/11\/01\/22\/00\/mon-1pm-arrhythmias-combined-aha-2022."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-022-07336-w","article-title":"Efficacy and safety of direct oral anticoagulants (DOACs) versus warfarin in atrial fibrillation patients with prior stroke: a systematic review and meta-analysis","volume":"37","author":"Umashankar K","year":"2023","unstructured":"Umashankar K, Mammi M, Badawoud E, et al.. Efficacy and safety of direct oral anticoagulants (DOACs) versus warfarin in atrial fibrillation patients with prior stroke: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2023, 37:1225-37. 10.1007\/s10557-022-07336-w","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.28091","article-title":"Heparin, bivalirudin, or the best of both for STEMI interventions","volume":"93","author":"Gilchrist IC","year":"2019","unstructured":"Gilchrist IC. Heparin, bivalirudin, or the best of both for STEMI interventions. Catheter Cardiovasc Interv. 2019, 93:248-9. 10.1002\/ccd.28091","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-024-07616-7","article-title":"Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with vitamin K antagonists in patients with atrial fibrillation and type 2 valvular heart disease: a systematic review and meta-analysis","volume":"29","author":"Liang X","year":"2024","unstructured":"Liang X, Liu S, Ji L, Ma F, Song G, Li F, Liu G. Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with vitamin K antagonists in patients with atrial fibrillation and type 2 valvular heart disease: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2024, 29:229-37. 10.1007\/s10557-024-07616-7","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03069-1","article-title":"Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism","volume":"21","author":"Yoon D","year":"2023","unstructured":"Yoon D, Jeong HE, Park S, You SC, Bang SM, Shin JY. Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism. BMC Med. 2023, 21:375. 10.1186\/s12916-023-03069-1","journal-title":"BMC Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14651","article-title":"Systematic review and meta-analysis: can we compare direct oral anticoagulants to warfarin in patients with atrial fibrillation and bio-prosthetic valves?","volume":"13","author":"Adhikari G","year":"2021","unstructured":"Adhikari G, Baral N, Rauniyar R, et al.. Systematic review and meta-analysis: can we compare direct oral anticoagulants to warfarin in patients with atrial fibrillation and bio-prosthetic valves?. Cureus. 2021, 13:14651. 10.7759\/cureus.14651","journal-title":"Cureus"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.7326\/M22-0318","article-title":"Apixaban versus rivaroxaban in patients with atrial fibrillation and valvular heart disease: a population-based study","volume":"175","author":"Dawwas GK","year":"2022","unstructured":"Dawwas GK, Cuker A, Barnes GD, Lewis JD, Hennessy S. Apixaban versus rivaroxaban in patients with atrial fibrillation and valvular heart disease: a population-based study. Ann Intern Med. 2022, 175:1506-14. 10.7326\/M22-0318","journal-title":"Ann Intern Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030620","article-title":"Risk factors and outcomes with progressive mitral annular calcification","volume":"12","author":"Lee HJ","year":"2023","unstructured":"Lee HJ, Seo J, Gwak SY, et al.. Risk factors and outcomes with progressive mitral annular calcification. J Am Heart Assoc. 2023, 12:030620. 10.1161\/JAHA.123.030620","journal-title":"J Am Heart Assoc"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/s13019-024-03009-x","article-title":"Stroke after heart valve surgery: a single center institution report","volume":"19","author":"Alwaqfi N","year":"2024","unstructured":"Alwaqfi N, AlBarakat MM, Qariouti H, Ibrahim K, Alzoubi N. Stroke after heart valve surgery: a single center institution report. J Cardiothorac Surg. 2024, 19:518. 10.1186\/s13019-024-03009-x","journal-title":"J Cardiothorac Surg"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"Guimar\u00e3es HP","year":"2020","unstructured":"Guimar\u00e3es HP, Lopes RD, de Barros E Silva PG, et al.. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020, 383:2117-26. 10.1056\/NEJMoa2029603","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23178","article-title":"Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial","volume":"42","author":"Guimar\u00e3es PO","year":"2019","unstructured":"Guimar\u00e3es PO, Pokorney SD, Lopes RD, et al.. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial. Clin Cardiol. 2019, 42:568-71. 10.1002\/clc.23178","journal-title":"Clin Cardiol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvz061","article-title":"Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial","volume":"6","author":"Nicolau AM","year":"2020","unstructured":"Nicolau AM, Corbalan R, Nicolau JC, et al.. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. Eur Heart J Cardiovasc Pharmacother. 2020, 6:167-75. 10.1093\/ehjcvp\/pvz061","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-023-07451-2","article-title":"Direct oral anticoagulants in patients with atrial fibrillation and significant mitral stenosis-a preliminary meta-analysis","volume":"38","author":"Zhang Y","year":"2024","unstructured":"Zhang Y, Chen M. Direct oral anticoagulants in patients with atrial fibrillation and significant mitral stenosis-a preliminary meta-analysis. Cardiovasc Drugs Ther. 2024, 38:1059-64. 10.1007\/s10557-023-07451-2","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euy174","article-title":"2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)","volume":"21","author":"Lip GY","year":"2019","unstructured":"Lip GY, Collet JP, Haude M, et al.. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2019, 21:192-3. 10.1093\/europace\/euy174","journal-title":"Europace"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euy151","article-title":"Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study","volume":"21","author":"Lip GY","year":"2019","unstructured":"Lip GY, Jensen M, Melgaard L, Skj\u00f8th F, Nielsen PB, Larsen TB. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study. Europace. 2019, 21:33-40. 10.1093\/europace\/euy151","journal-title":"Europace"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000001013","article-title":"Anticoagulation for rheumatic mitral stenosis, INVICTUS in perspective","volume":"38","author":"Verma R","year":"2023","unstructured":"Verma R, Latter DA. Anticoagulation for rheumatic mitral stenosis, INVICTUS in perspective. Curr Opin Cardiol. 2023, 38:55-60. 10.1097\/HCO.0000000000001013","journal-title":"Curr Opin Cardiol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvx028","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis","volume":"4","author":"Caldeira D","year":"2018","unstructured":"Caldeira D, David C, Costa J, Ferreira JJ, Pinto FJ. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2018, 4:111-8. 10.1093\/ehjcvp\/pvx028","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-024-02517-z","article-title":"Favorable safety profile of NOAC therapy in patients after tricuspid transcatheter edge-to-edge repair","author":"Hoerbrand IA","year":"2024","unstructured":"Hoerbrand IA, Kraus MJ, Gruber M, Geis NA, Schlegel P, Frey N, Konstandin MH. Favorable safety profile of NOAC therapy in patients after tricuspid transcatheter edge-to-edge repair. Clin Res Cardiol. 2024, 10.1007\/s00392-024-02517-z","journal-title":"Clin Res Cardiol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23142","article-title":"Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry","volume":"42","author":"Contreras JP","year":"2019","unstructured":"Contreras JP, Hong KN, Castillo J, et al.. Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry. Clin Cardiol. 2019, 42:339-45. 10.1002\/clc.23142","journal-title":"Clin Cardiol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-024-03021-x","article-title":"The use of non-vitamin K antagonist oral anticoagulants in chronic thromboembolic pulmonary hypertension: an updated meta-analysis","volume":"57","author":"Wu D","year":"2024","unstructured":"Wu D, Liang H, Kaisaier W, et al.. The use of non-vitamin K antagonist oral anticoagulants in chronic thromboembolic pulmonary hypertension: an updated meta-analysis. J Thromb Thrombolysis. 2024, 57:1256-67. 10.1007\/s11239-024-03021-x","journal-title":"J Thromb Thrombolysis"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2021.07.034","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic valves: a meta-analysis","volume":"165","author":"Yokoyama Y","year":"2023","unstructured":"Yokoyama Y, Briasoulis A, Ueyama H, et al.. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic valves: a meta-analysis. J Thorac Cardiovasc Surg. 2023, 165:2052-2059.e4. 10.1016\/j.jtcvs.2021.07.034","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-013-1048-z","article-title":"Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials","volume":"38","author":"Amin A","year":"2014","unstructured":"Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis. 2014, 38:150-9. 10.1007\/s11239-013-1048-z","journal-title":"J Thromb Thrombolysis"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-024-04392-y","article-title":"Recurrent strokes after transcatheter aortic valve replacement in an elderly patient with severe bicuspid aortic valve stenosis: a case report","volume":"24","author":"Meng X","year":"2024","unstructured":"Meng X, Wang X, Yang C, Zhang H, Zhong Y, Wang F. Recurrent strokes after transcatheter aortic valve replacement in an elderly patient with severe bicuspid aortic valve stenosis: a case report. BMC Cardiovasc Disord. 2024, 24:731. 10.1186\/s12872-024-04392-y","journal-title":"BMC Cardiovasc Disord"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-015-0919-z","article-title":"Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves","volume":"105","author":"Yadlapati A","year":"2016","unstructured":"Yadlapati A, Groh C, Malaisrie SC, Gajjar M, Kruse J, Meyers S, Passman R. Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves. Clin Res Cardiol. 2016, 105:268-72. 10.1007\/s00392-015-0919-z","journal-title":"Clin Res Cardiol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.899906","article-title":"An updated meta-analysis of DOACs vs. VKAs in atrial fibrillation patients with bioprosthetic heart valve","volume":"9","author":"Cao Y","year":"2022","unstructured":"Cao Y, Zheng Y, Li S, Liu F, Xue Z, Yin K, Luo J. An updated meta-analysis of DOACs vs. VKAs in atrial fibrillation patients with bioprosthetic heart valve. Front Cardiovasc Med. 2022, 9:899906. 10.3389\/fcvm.2022.899906","journal-title":"Front Cardiovasc Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano RP","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al.. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013, 369:2093-104. 10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm391","article-title":"Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II","volume":"28","author":"Koertke H","year":"2007","unstructured":"Koertke H, Zittermann A, Tenderich G, et al.. Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II. Eur Heart J. 2007, 28:2479-84. 10.1093\/eurheartj\/ehm391","journal-title":"Eur Heart J"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom JW","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, et al.. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013, 369:1206-14. 10.1056\/NEJMoa1300615","journal-title":"N Engl J Med"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2022.03.037","article-title":"RIvaroxaban in mitral stenosis (RISE MS): a pilot randomized clinical trial","volume":"356","author":"Sadeghipour P","year":"2022","unstructured":"Sadeghipour P, Pouraliakbar H, Parsaee M, et al.. RIvaroxaban in mitral stenosis (RISE MS): a pilot randomized clinical trial. Int J Cardiol. 2022, 356:83-6. 10.1016\/j.ijcard.2022.03.037","journal-title":"Int J Cardiol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw027","article-title":"Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial","volume":"37","author":"Mattle HP","year":"2016","unstructured":"Mattle HP, Evers S, Hildick-Smith D, et al.. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. Eur Heart J. 2016, 37:2029-36. 10.1093\/eurheartj\/ehw027","journal-title":"Eur Heart J"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.2174\/1871525720666220321120944","article-title":"Anticoagulation in atrial fibrillation associated with mitral stenosis","volume":"20","author":"da Silva RM","year":"2022","unstructured":"da Silva RM. Anticoagulation in atrial fibrillation associated with mitral stenosis. Cardiovasc Hematol Agents Med Chem. 2022, 20:172-4. 10.2174\/1871525720666220321120944","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1080\/10408347.2020.1839735","article-title":"Review on characteristics and analytical methods of rivaroxaban","volume":"52","author":"Re\u00e7ber T","year":"2022","unstructured":"Re\u00e7ber T, Haznedaro\u011flu \u0130C, \u00c7elebier M. Review on characteristics and analytical methods of rivaroxaban. Crit Rev Anal Chem. 2022, 52:865-77. 10.1080\/10408347.2020.1839735","journal-title":"Crit Rev Anal Chem"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/341935-optimizing-anticoagulation-strategies-in-patients-with-atrial-fibrillation-and-valvular-heart-disease-a-comprehensive-evidence-based-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T05:18:26Z","timestamp":1743139106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/341935-optimizing-anticoagulation-strategies-in-patients-with-atrial-fibrillation-and-valvular-heart-disease-a-comprehensive-evidence-based-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":69,"URL":"https:\/\/doi.org\/10.7759\/cureus.81319","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,27]]}}}